Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Rapid correction of low vitamin D status in nursing home residents 3. 2008 Exclusive Survey—Earnings: Good news for primary care income 4. Medicare pay-for-reporting effort draws fire from frustrated doctors 5. Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment
Top Ten Searches
rheumatoid arthritis lupus polymyalgia sjogrens fibromyalgia amyloidosis vasculitis urate raynauds myositisYour Article Summary
Hematologic manifestations and predictors of lymphoma development in primary Sjogren syndrome: clinical and pathophysiologic aspects
Medicine, 09/15/09
Baimpa E et al. – Anemia of chronic disease and hypergammaglobulinemia are common hematologic manifestations at diagnosis and during the course of pSS. Neutropenia and cryoglobulinemia at diagnosis are significantly associated with an increased risk of lymphoma development.
Methods- Retrospective study of 536 consecutive patients
- Prevalence of hematologic abnormalities and their associations with various disease manifestations in pSS assessed
- Risk factors for the development of non-Hodgkin lymphoma (NHL) overall and by subtype identified
- Anemia of chronic disease and hypergammaglobulinemia were the most prevalent hematologic manifestations during the course of pSS.
- Lymphoma was diagnosed in 7.5% of patients
- Marginal zone B-cell lymphomas (MZBCLs) were the predominant histologic type 65%
- while diffuse large B-cell lymphomas (DLBCLs) accounted for 17.5% of all cases
- Development of NHL in patients with pSS could be predicted by the presence of simple clinical and laboratory factors at diagnosis: neutropenia , cryoglobulinemia , splenomegaly , lymphadenopathy , and low C4 levels
- Patients carrying these factors had more than 5-fold increased risk of NHL compared to patients with no risk factors
- Disease characteristics could predict subsequent development of MZBCL
- Presence of lymphocytopenia at diagnosis served as risk factor for the development of a non-MZBCL
Today in Autoimmune/Heritable...keeping you current
Receive free subspecialty "5-minute updates" via email
Clinical and histologic evidence of salivary gland restoration supports the efficacy of rituximab treatment in Sjögrens syndrome
Arthritis & Rheumatism, 11/06/09
Vaccination, atherosclerosis and systemic lupus erythematosus
Lupus, 11/05/09
Dabigatran, a direct thrombin inhibitor, demonstrates antifibrotic effects on lung fibroblasts
Arthritis & Rheumatism, 11/11/09
Today in Basic Science/Genetics...keeping you current
Receive free subspecialty "5-minute updates" via email
Hepatoprotective effect of TNF-alpha blockade in psoriatic arthritis: A cross-sectional study
Annals of Rheumatic Diseases, 11/09/09
Musculoskeletal manifestations in patients with malignant disease
Clinical Rheumatology, 11/13/09
The relationship between synovial lymphocyte aggregates and the clinical response to infliximab in rheumatoid arthritis: A prospective study
Arthritis & Rheumatism, 11/04/09
Sponsor
Article Search
Sponsor


See Latest Articles


